Complete Wegovy vs Mounjaro UK Dosage Chart Comparison
Wegovy vs Mounjaro Dosage Chart: Key Differences for UK Buyers
The fundamental difference in Wegovy vs Mounjaro dosage charts lies in their escalation timeframes and mechanisms of action. Wegovy follows a 20-week programme with 5 distinct doses: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg maintenance from week 17 onwards. Mounjaro uses a shorter 12-week escalation with 4 doses: 2.5mg (weeks 1-4), 5mg (weeks 5-8), 10mg (weeks 9-12), with optional 15mg maintenance for those requiring higher efficacy.
This difference in Wegovy vs Mounjaro dosage progression reflects their distinct pharmacological profiles. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics natural fullness hormones, requiring gradual dose increases to minimise gastrointestinal side effects. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist, which may work more rapidly but still requires careful dose escalation. Both prescription-only medicines must be used alongside a reduced-calorie diet and increased physical activity for optimal results.
UK Pricing Breakdown: Wegovy vs Mounjaro Dosage Chart Costs
When comparing Wegovy vs Mounjaro dosage chart pricing in the UK, Wegovy offers transparent pricing through EverydayMeds starting at £79.99 for the 0.25mg starter dose. The complete Wegovy escalation costs: 0.25mg £79.99, 0.5mg £94.99, 1mg £99.99, 1.7mg £139.99, and maintenance 2.4mg £209.99. Our Intro Trio bundle (0.25mg, 0.5mg, 1mg) provides the first 12 weeks for £299.99, whilst the Ultimate Stability Trio offers three months of maintenance 2.4mg doses for £649.99.
Mounjaro pricing varies significantly across UK suppliers, but our focus remains on providing exceptional value for Wegovy through our GPhC-registered pharmacy (#9012878). New customers can apply discount code FIRST40 at checkout to reach these competitive prices, whilst returning customers use DOSE25. The convenience bundles eliminate the need for multiple orders, ensuring uninterrupted treatment progression through your chosen Wegovy vs Mounjaro dosage schedule.
Clinical Evidence Behind Wegovy vs Mounjaro Dosage Charts
The Wegovy vs Mounjaro dosage chart comparison is supported by robust clinical evidence from separate trial programmes. Wegovy's dosing schedule was established through the STEP trial programme, with STEP 1 demonstrating that participants achieved approximately 15% average weight loss at 68 weeks when following the prescribed dose escalation alongside lifestyle modifications. The gradual escalation to 2.4mg maintenance proved optimal for balancing efficacy with tolerability.
Mounjaro's dosage progression was validated through the SURMOUNT trials, showing effectiveness across its dose ranges. However, direct comparison of trial outcomes between Wegovy vs Mounjaro dosage schedules isn't appropriate due to different trial designs, participant populations, and endpoints, as noted by Wilding et al., NEJM, 2021. Both treatments are available from EverydayMeds, and your prescriber can help determine which dosage chart aligns with your medical profile.
How Wegovy's Dosage Schedule Supports Weight Management
Wegovy's carefully structured dosage chart works by gradually increasing semaglutide levels to optimise GLP-1 receptor activation in the brain's appetite centres. Starting with 0.25mg allows your body to adapt to the medication's appetite-suppressing effects, reducing nausea and other gastrointestinal side effects commonly experienced when GLP-1 receptor agonists are introduced too rapidly. Each 4-week dose increment in the Wegovy schedule allows time for physiological adaptation whilst progressively enhancing the medication's ability to promote satiety after smaller meals. The 2.4mg maintenance dose represents the optimal therapeutic level for long-term weight management, as demonstrated in clinical trials where participants maintained significant weight loss when continuing treatment. This graduated approach distinguishes Wegovy's dosage methodology from other weight management approaches, providing sustainable appetite control that supports lasting lifestyle changes.
Streamlined UK Ordering Process for Wegovy vs Mounjaro Dosage Charts
Accessing either treatment through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, designed to evaluate your suitability for these prescription-only medicines. Our qualified UK prescribers review your medical history, current medications, and weight management goals to determine the most appropriate starting dose from the Wegovy vs Mounjaro dosage options. Standard prescriber reviews are completed within 3 working days, with express 24-hour review available for urgent requirements. Once approved, your medication is dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. This efficient process ensures you can begin your chosen dosage schedule promptly whilst maintaining the highest clinical safety standards throughout your treatment journey.
Storage and Practical Considerations: Wegovy vs Mounjaro Dosage Implementation
When implementing your chosen Wegovy vs Mounjaro dosage chart, storage requirements present a key practical difference between these treatments. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but offer exceptional convenience with 6 weeks of room temperature stability below 30°C once removed from refrigeration. This storage advantage makes Wegovy particularly suitable for frequent travellers or those with busy lifestyles who may need dosage flexibility. Each Wegovy pen uses Novo Nordisk's FlexTouch injection system, pre-loaded with 4 doses per pen, and features clear dose markings that correspond to your position on the dosage escalation chart. The weekly injection schedule fits seamlessly into most routines, and the pen's intuitive design ensures accurate dose delivery throughout your progression from starter 0.25mg through to maintenance 2.4mg levels.
Personalised Wegovy vs Mounjaro Dosage Chart Selection for UK Patients
Choosing between Wegovy vs Mounjaro dosage schedules requires consideration of individual factors beyond simple dose comparison charts. Your medical history, previous weight management attempts, concurrent medications, and personal preferences all influence which dosage progression may suit you best. Some patients prefer Wegovy's longer, more gradual escalation period as it allows extended adaptation time and may reduce side effect intensity during the initial months.
Others may favour Mounjaro's more rapid progression to therapeutic doses, particularly if they have previous experience with GLP-1 medications or require faster clinical intervention. Our prescribers at EverydayMeds evaluate these individual factors during consultation, ensuring your selected Wegovy vs Mounjaro dosage chart aligns with your specific clinical needs. This personalised approach optimises treatment outcomes whilst maintaining safety throughout your weight management journey with either prescription-only medicine.
Start Your Wegovy Dosage Journey Today with EverydayMeds
Ready to begin your weight management journey with a clinically-proven dosage schedule? EverydayMeds makes accessing Wegovy simple through our MHRA-compliant online service, backed by our GPhC-registered pharmacy (#9012878). New customers can use discount code FIRST40 at checkout to access competitive pricing starting from £79.99 for your initial 0.25mg dose, whilst returning customers benefit from code DOSE25 for ongoing treatment. Our clinical team provides comprehensive support throughout your dosage progression, ensuring safe escalation from starter doses through to maintenance levels. Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment and receive expert guidance on implementing your personalised Wegovy dosage chart. Transform your approach to weight management with professional medical support and genuine Novo Nordisk Wegovy delivered directly to your door.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
